

02D0

Docket No. 17327CIP(HL)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Pacifici et al

Serial No. 09/552,823

Filed: April 20, 2000

For: USE OF RETINOID RECEPTOR ANTAGONISTS
OR AGONISTS IN THE TREATMENT OF CARTILAGE
BONE PATHOLOGIES

Group Art Unit: Not Assigned

Examiner: Not Assigned

TRANSMITTAL SHEETBox IDS-Non-Fee
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- 1) PTO Form 1449 with forty-nine (49) references (3 pgs.) (References not included)
- 2) Information Disclosure Statement (2 pgs.)
- 3) Return/Stamped Postcard

Respectfully Submitted,


Date:

May 8, 2000

Signature:

Carlos A. Fisher

Carlos A. Fisher
Registration No. 36,510
Legal Department, T2-7H
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612
Telephone: (714) 246-4920
Fax: (714) 246-4249CERTIFICATE OF MAILINGI hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box
IDS-Non-Fee, Assistant Commissioner for Patents, Washington, D.C. 20231 on5/9/00
(Date of Deposit)Bonnie Ferguson
Name of person mailing correspondence5/9/00
Date of SignatureBonnie Ferguson
Signature



Handwritten: #2
7/5/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pacifici et al)

Group Art Unit: Not yet assigned

Serial No.: 09/552,823)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box IDS-Non-Fee; Assistant Commissioner for Patents, Washington, D.C. 20231 on:

Filed: April 20, 2000)

Date of Deposit: 5/9/00

For: Use of Retinoid Receptor
Antagonists or Agonists in the
Treatment of Cartilage Bone
Pathologies)

Person making Deposit: Bonnie FergusonSignature: Bonnie FergusonDate of Signature: 5/9/00

Examiner: Not yet assigned)

INFORMATION DISCLOSURE STATEMENT

Box IDS-Non Fee Amendment
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Pursuant to 37 CFR § 1.98(d), copies of any patent publication or other information are not required to be provided if they were previously cited by or submitted to the Patent and Trademark Office in a prior application to which priority is claimed under 35 USC § 120.

An Information Disclosure Statement consisting of 5 pages was filed on May 8, 2000 in parent application serial number 09/464,344. Copies of the references provided during prosecution of the parent application which were cited therein are not included with this IDS.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

As this Information Disclosure Statement is being submitted prior to three months after the filing date of this Application, no fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Date: May 8, 2000

Carlos A. Fisher
Carlos A. Fisher
Reg. No. 36,510
ALLERGAN, INC.
T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4920
Fax: 714-246-4249